Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support

Niklas GebauerDepartment of Internal Medicine I, University Hospital of Schleswig-Holstein, Luebeck, Germany; Correspondence[email protected]

Harald BiersackDepartment of Internal Medicine I, University Hospital of Schleswig-Holstein, Luebeck, Germany;

Ann-Cathrin CzerwinskaDepartment of Pathology, Reference Centre for Lymph Node Pathology and Hematopathology, University Hospital of Schleswig-Holstein, Luebeck, Germany;

Janina SchemmeDepartment of Pathology, Reference Centre for Lymph Node Pathology and Hematopathology, University Hospital of Schleswig-Holstein, Luebeck, Germany;

Tim Tristan HardelDepartment of Internal Medicine I, University Hospital of Schleswig-Holstein, Luebeck, Germany;

Veronica BernardDepartment of Pathology, Reference Centre for Lymph Node Pathology and Hematopathology, University Hospital of Schleswig-Holstein, Luebeck, Germany;

Dirk RadesDepartment of Radiation Oncology, University Hospital of Schleswig-Holstein, Luebeck, Germany

Hendrik LehnertDepartment of Internal Medicine I, University Hospital of Schleswig-Holstein, Luebeck, Germany;

Kim Barbara LuleyDepartment of Internal Medicine I, University Hospital of Schleswig-Holstein, Luebeck, Germany;

Christoph ThornsDepartment of Pathology, Reference Centre for Lymph Node Pathology and Hematopathology, University Hospital of Schleswig-Holstein, Luebeck, Germany;

show all

Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date